RRN3 Antibody

What is RRN3 and why is it important in cellular research?

RRN3 is an RNA polymerase I-specific transcription factor essential for ribosomal DNA (rDNA) transcription. It functions by enabling the formation of the competent pre-initiation complex (PIC) required for efficient transcription initiation by RNA polymerase I . The importance of RRN3 lies in its crucial role in ribosome biogenesis, which directly impacts cellular growth and proliferation.

RRN3 was initially identified in yeast (Saccharomyces cerevisiae) but has been shown to be functionally conserved in humans, with the human homologue displaying 21% amino acid identity to the yeast protein . This conservation suggests that RRN3 mediates fundamental mechanisms regulating rRNA synthesis across eukaryotes. The discovery that RRN3 is a DNA-binding protein with a domain similar to heat shock transcription factor 2 has expanded our understanding of its molecular function .

What are the key structural features of RRN3 that antibodies typically target?

RRN3 contains several functionally important domains that antibodies may target:

• DNA-binding domain (amino acids 382-400 in human RRN3) - This region contains a helix-turn-helix motif with sequence similarity to the DNA binding domain of heat shock transcription factor 2 .

• Interaction domains for RNA polymerase I (specifically rpa43) and SL1/TAF I68 - These regions enable RRN3 to perform its bridging function between polymerase and template-bound factors .

• C-terminal region (amino acids 550-650) - This region is targeted by some commercial antibodies like ab251933 and may be important for protein folding or regulation .

Antibodies raised against different epitopes can provide insights into different aspects of RRN3 function, with some potentially blocking specific interactions while preserving others.

How does the human RRN3 differ from its yeast counterpart, and what implications does this have for antibody selection?

The human RRN3 shares 21% sequence identity with the yeast protein, though they are highly functionally conserved . Key differences include:

Despite these differences, the strong functional conservation means that antibodies targeting highly conserved epitopes may work across species, while those targeting variable regions will be species-specific .

What are the validated applications for RRN3 antibodies in research settings?

Based on the available information, RRN3 antibodies have been validated for several experimental applications:

• Immunohistochemistry on paraffin-embedded tissues (IHC-P) - Proven effective for visualizing RRN3 localization in tissue sections, such as human cerebellum, using a dilution of 1/200 .

• Immunocytochemistry/Immunofluorescence (ICC/IF) - Successfully used to detect RRN3 in fixed and permeabilized cells, such as MCF7 (human breast adenocarcinoma cell line) at a concentration of 4 μg/ml .

• Western blotting - Although not explicitly mentioned in the search results for the antibody ab251933, Western blot analysis has been used to detect recombinant RRN3 proteins in research settings .

• Co-immunoprecipitation - RRN3 interactions with other proteins, such as rpa43 and TAF I68, have been studied using immunoprecipitation techniques with epitope-tagged versions of RRN3 .

Each application requires specific optimization of antibody concentration, fixation methods, and detection systems for optimal results.

What methodological considerations are critical when using RRN3 antibodies for immunocytochemistry?

When performing immunocytochemistry or immunofluorescence with RRN3 antibodies, researchers should consider:

How can researchers optimize immunohistochemistry protocols for RRN3 detection in tissue samples?

For optimal RRN3 detection in tissue samples using immunohistochemistry:

• Tissue preparation - Paraffin-embedded tissues have been successfully used for RRN3 IHC. Ensure proper fixation (typically 10% neutral buffered formalin) and paraffin embedding procedures .

• Antigen retrieval - Although specific conditions aren't mentioned in the search results, heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is typically necessary for formalin-fixed tissues.

• Blocking - Use appropriate blocking solutions (typically 5-10% normal serum from the species of the secondary antibody) to reduce background staining.

• Antibody dilution - A 1/200 dilution has been validated for the ab251933 antibody on human cerebellum sections . Titration may be required for other tissues.

• Detection system - Select an appropriate detection system based on your microscopy capabilities and the level of sensitivity required.

• Counterstaining - Consider using hematoxylin or other nuclear counterstains to provide tissue context for RRN3 expression patterns.

What are common challenges when working with RRN3 antibodies and how can they be addressed?

When working with RRN3 antibodies, researchers may encounter several challenges:

• Background staining - This may be addressed by:

  • Increasing blocking time or concentration

  • Optimizing antibody dilution

  • Performing additional washing steps

  • Using more specific detection systems

• Weak or absent signal - Potential solutions include:

  • Optimizing antigen retrieval methods

  • Reducing antibody dilution

  • Extending primary antibody incubation time

  • Ensuring target protein is expressed in the sample being tested

• Cross-reactivity - While the search results don't specifically mention cross-reactivity issues with RRN3 antibodies, researchers should:

  • Validate antibody specificity using positive and negative controls

  • Consider using knockout or knockdown samples as controls

  • Perform Western blot analysis to confirm antibody specificity

• Inconsistent results - Standardize protocols, including fixation times, blocking conditions, and detection methods to improve reproducibility.

What validation steps should researchers take before using a new lot of RRN3 antibody?

Before implementing a new lot of RRN3 antibody in critical experiments, researchers should:

• Perform Western blot analysis using positive control samples (cells or tissues known to express RRN3) to confirm the antibody recognizes a protein of the expected molecular weight.

• Compare staining patterns with previous lots using parallel immunostaining of the same sample types.

• Verify nuclear/nucleolar localization pattern consistent with RRN3's known function in ribosomal DNA transcription.

• Test functional blocking if using the antibody to inhibit RRN3 activity in functional assays.

• Consider appropriate negative controls, such as:

  • Preincubation with immunizing peptide (if available)

  • Use on samples with known low or absent RRN3 expression

  • IgG controls from the same species

How can researchers distinguish between specific and non-specific binding when using RRN3 antibodies?

To distinguish between specific and non-specific binding:

• Localization pattern - RRN3 is primarily nucleolar/nuclear due to its role in rDNA transcription. Any significant cytoplasmic staining should be critically evaluated.

• Competition assays - Preincubation of the antibody with the immunizing peptide should abolish specific staining while non-specific binding may persist.

• Multiple antibodies - Using antibodies targeting different epitopes of RRN3 should yield similar staining patterns if binding is specific.

• Correlation with known biology - Staining patterns should be consistent with the known biology of RRN3, including higher expression in actively growing cells.

• Knockout/knockdown controls - Reduced or absent staining in samples with reduced RRN3 expression provides strong evidence of specificity.

How can RRN3 antibodies be utilized to study the DNA-binding properties of RRN3?

The discovery that RRN3 possesses DNA-binding capabilities opens new research avenues . Researchers can utilize RRN3 antibodies to:

• Perform chromatin immunoprecipitation (ChIP) assays to identify genomic regions bound by RRN3 in vivo.

• Conduct electrophoretic mobility shift assays (EMSAs) with purified RRN3 and specific DNA sequences, using the antibody for supershift assays to confirm binding specificity.

• Develop ChIP-sequencing approaches to map the genome-wide binding profile of RRN3.

• Create immunofluorescence co-localization studies with markers of active rDNA transcription to visualize RRN3-DNA interactions in the nucleolus.

• Conduct immunoprecipitation followed by DNA extraction and sequencing to identify DNA sequences associated with RRN3 in vivo.

These approaches would particularly benefit from antibodies targeting regions outside the DNA-binding domain to avoid interference with DNA binding.

What insights can be gained by comparing RRN3 expression and activity across different species using antibodies?

Research has shown that human RRN3 can functionally complement yeast strains with RRN3 gene disruption, despite only 21% sequence identity . Using antibodies to study RRN3 across species can provide:

• Evolutionary insights into conserved mechanisms of ribosomal DNA transcription regulation.

• Identification of conserved versus species-specific interaction partners through co-immunoprecipitation studies.

• Comparative analysis of RRN3 expression patterns in different tissues and developmental stages across species.

• Evaluation of differential responses to growth conditions or stress across species.

• Structure-function relationships by correlating antibody epitope recognition with functional conservation.

Antibodies recognizing conserved epitopes would be particularly valuable for cross-species studies, while those targeting species-specific regions could highlight evolutionary adaptations.

How can RRN3 antibodies contribute to understanding the regulation of ribosomal DNA transcription in response to cellular growth conditions?

RRN3 activity is growth-dependent, making it a key factor in coupling cellular growth signals to ribosome synthesis . RRN3 antibodies can help researchers:

• Monitor changes in RRN3 protein levels, subcellular localization, or post-translational modifications in response to different growth conditions.

• Investigate dynamic interactions between RRN3 and RNA polymerase I or SL1 under varying growth conditions through co-immunoprecipitation studies.

• Analyze RRN3 binding to rDNA promoters under different cellular states using ChIP approaches.

• Study the formation of the pre-initiation complex in response to growth signals using immunofluorescence co-localization.

• Investigate potential regulatory phosphorylation events on RRN3 using phospho-specific antibodies (if available) or general RRN3 antibodies following phosphatase treatments.

These approaches can provide mechanistic insights into how growth signals are integrated at the level of ribosomal RNA synthesis, a fundamental process for cellular growth and proliferation.

What role might RRN3 play in disease states, and how can antibodies help investigate this?

While the search results don't specifically address RRN3's role in disease, its fundamental function in ribosomal RNA synthesis suggests potential implications in:

• Cancer biology - Dysregulated ribosome biogenesis is a hallmark of many cancers. RRN3 antibodies could help:

  • Compare RRN3 expression and localization in normal versus malignant tissues

  • Evaluate RRN3 as a potential biomarker for proliferative disorders

  • Investigate RRN3 as a potential therapeutic target

• Neurodegenerative diseases - The presence of RRN3 in cerebellum suggests neuronal expression, potentially linking ribosome biogenesis to neurodegeneration.

• Developmental disorders - Given the fundamental role of ribosomes in growth, developmental abnormalities might involve RRN3 dysfunction.

Researchers could use RRN3 antibodies in tissue microarrays, patient-derived samples, and model systems to investigate these potential disease connections.

How might studying the DNA-binding domain mutants of RRN3 advance our understanding of transcription regulation?

The identification of RRN3 as a DNA-binding protein with a domain showing similarity to heat shock transcription factor 2 opens new research avenues . Researchers could:

• Generate a panel of domain-specific antibodies to study how mutations affect RRN3 conformation and interactions.

• Use existing antibodies to compare wild-type and mutant RRN3 localization and chromatin association.

• Perform structural studies with antibody fragments to understand the conformational changes resulting from DNA-binding domain mutations.

• Investigate whether DNA binding is regulated through post-translational modifications using site-specific antibodies.

• Study potential binding site competition between RRN3 and other transcription factors using ChIP-seq approaches with specific antibodies.

Understanding the specific DNA sequences bound by RRN3 and how this binding contributes to transcriptional regulation would significantly advance the field.

How can new technologies in antibody development enhance RRN3 research?

Emerging antibody technologies could significantly advance RRN3 research:

• Single-domain antibodies (nanobodies) - These could provide access to epitopes inaccessible to conventional antibodies and might penetrate living cells for real-time imaging of RRN3 dynamics.

• Bi-specific antibodies - These could simultaneously target RRN3 and interaction partners to study complex formation in situ.

• Proximity labeling antibodies - Conjugating RRN3 antibodies with enzymes like BioID or APEX2 could identify proximal proteins and DNA sequences in living cells.

• Conformation-specific antibodies - These could distinguish between active and inactive RRN3 states, potentially correlating with growth conditions.

• Intrabodies - Expressing RRN3-targeting antibody fragments within cells could provide new approaches to modulate RRN3 function in vivo.